IQVIA offers an attractively priced franchise with a perfect four-quarter earnings beat streak and exceptional free cash flow conversion, but a confirmed technical breakdown and negative price momentum mean fundamental quality and chart reality are in direct conflict, warranting patience before adding exposure.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Attractive Valuation Low Peg↑Improving
- Superior Free Cash Conversion↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026· older than 90 days
IQVIA Holdings, Inc. (IQV) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $262.59, but acceptable to hold if already in. Reasons: Thin upside margin: 6.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5).
IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies through three business segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — serving over... Read more
Hold if already holding. Not a fresh buy at $262.59, but acceptable to hold if already in. Reasons: Thin upside margin: 6.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5). Chart setup: RSI 50 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.2/10, high confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 99d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 27, 2026Recent Developments — IQVIA Holdings, Inc.
Latest news
- NEWS IQVIA Holdings (IQV) Shares Rise Premarket After Q3 Earnings Bea - GuruFocus — GuruFocus Oct 27, 2026 positive
- NEWS IQVIA Holdings Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:IQV) 2026-10-27 - Seeking Alpha — Seeking Alpha Oct 27, 2026 neutral
- NEWS IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y - TradingView — TradingView Oct 27, 2026 positive
- NEWS IQVIA gains as R&D Solutions drive Q3 beat - Seeking Alpha — Seeking Alpha Oct 27, 2026 positive
- NEWS IQVIA stock gains as R&D Solutions drive Q3 beat (IQV:NYSE) - Seeking Alpha — Seeking Alpha Oct 27, 2026 positive
Latest item Oct 27, 2026 · Generated 2026-11-04T11:59:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02LOWStockholders approved the 2026 Incentive and Stock Award Plan at the April 23, 2026 Annual Meeting. Plan replaces the 2017 Incentive and Stock Award Plan; authorizes stock options, RSUs, restricted stock awards, and performance-based RSUs based on Committee-selected metrics.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $262.59, but acceptable to hold if already in. Reasons: Thin upside margin: 6.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5). Chart setup: RSI 50 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $280.70 (+6.9%), stop $244.81 (−7.3%), A.R:R 0.9:1. Score 5.2/10, high confidence.
Analyst target: $280.70 (+6.9% upside). Analyst target $280.70 (+6.9%), stop $244.81 (−7.3%), A.R:R 0.9:1. Stop-loss: $244.81.
Thin upside margin: 6.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5); Leverage penalty (D/E 2.4): -1.5.
IQVIA Holdings, Inc. trades at a P/E of 31.9 (forward 18.5). TrendMatrix value score: 5.9/10. Verdict: Hold.
26 analysts rate IQV, with a consensus score of 4.3/5. 18 analysts publish price targets averaging $312.
What does IQVIA Holdings, Inc. do?IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies...
IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences companies through three business segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — serving over 10,000 clients in more than 100 countries, including nearly all top 100 global pharmaceutical companies, with approximately 93,000 employees worldwide.